Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE

Christine Bengtsson0 个研究点开始时间: 2015年3月18日最近更新: 2017年5月22日

适应症

试验速览

暂无简介。

•Male or female, 18-65 years of age, who has given written consent for his/her par-ticipation to the study
•ACR criteria for RA and SLE
•< 10mg Prednisolon daily doses
•Low-medium disease activity DAS28 <4.6-RA, SLEDAI-2k <6 SLE (Arthritis accepted)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 44
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

•Antimalarial medication less than5 ½-t= 250 days before study inclusion visit
•High disease activity, where cortison ad-justment is predictable
•Pleuritis or Pericarditis – SLE
•Impaired visus and/or colour vision
•Hypertension >160/95
•Short life expectancy due to other comor-bidity
•Documented allergy or intolerance to study drug
•Severe psychiatric condition or other reason that jeopardize compliance with fol-low up.
•On fertile females, pregnancy assessed by anamnesis and pregnancy test

发起方

Christine Bengtsson